New York, NY – September 8, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced its corporate sponsorship of the upcoming Alzheimer’s Foundation of America’s 5 Boroughs Concepts in Care Conference. The free educational conference, which takes place in New York City at the Sheraton Times Square Hotel on Friday, September 12, 2014, will bring together family caregivers, healthcare professionals and individuals with Alzheimer’s disease. Experts in the field are scheduled to make presentations and attendees will receive first-hand perspectives on the medical, behavioral and practical issues faced by people with Alzheimer’s disease and those around them.
“Anavex values the efforts of the Alzheimer’s Foundation of America in providing care and services to individuals with dementia along with their families and caregivers,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “Early screening is an important step for treatment. To that end, we are very pleased to be joining together with the Alzheimer’s Foundation to offer the community a memory screening room at the conference.”
Additional information about the conference is available from the Alzheimer’s Foundation of America website.
About Alzheimer’s Foundation of America
The Alzheimer’s Foundation of America (AFA) was founded by a consortium of organizations to fill the gap that existed on a national level to assure quality of care and excellence in service to individuals with Alzheimer’s disease and related illnesses, and to their caregivers and families. AFA unites more than 1,700 member organizations from coast-to-coast that are dedicated to meeting the educational, social, emotional and practical needs of individuals with Alzheimer’s disease and related illnesses, and their caregivers and families. Under AFA’s umbrella, these organizations collaborate on education, resources, best practices and advocacy —all resulting in better care for people affected by the disease.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a clinical-stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s disease, other CNS diseases and various types of cancer. ANAVEX 2-73, an orally available drug candidate developed to treat Alzheimer’s disease through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg. Results from preclinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties. A highly encouraging synergistic effect has also been observed between ANAVEX 2-73 and donepezil (Aricept®). The combined therapeutic, called ANAVEX PLUS, produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually. Anavex is a publicly traded corporation quoted as AVXL.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information
Anavex Life Sciences Corp.
Research & Business Development